000126975 001__ 126975
000126975 005__ 20241125101143.0
000126975 0247_ $$2doi$$a10.3390/cancers15133367
000126975 0248_ $$2sideral$$a134454
000126975 037__ $$aART-2023-134454
000126975 041__ $$aeng
000126975 100__ $$aMartínez-Domínguez, Samuel J.$$uUniversidad de Zaragoza
000126975 245__ $$aLiver fibrosis in non-alcoholic fatty liver disease and progression to hepatocellular carcinoma in patients with inflammatory bowel disease: a systematic review
000126975 260__ $$c2023
000126975 5060_ $$aAccess copy available to the general public$$fUnrestricted
000126975 5203_ $$aThe aim of the systematic review is to assess the prevalence and risk factors of liver fibrosis in patients with Inflammatory Bowel Disease (IBD) and Non-Alcoholic Fatty Liver Disease (NAFLD) and to discuss the role of liver fibrosis in the progression to hepatocellular carcinoma (HCC). We performed a structured search in PubMed, Web of Science, Embase, and Scopus up to 3 March 2023 to identify observational studies reporting liver fibrosis in patients with NAFLD and IBD. Quality of studies was assessed using the Newcastle-Ottawa Scale (NOS) score. A total of 23 studies met our inclusion criteria, including 629,781 patients. A total of 10 cross-sectional, 3 case-control, and 10 cohort studies were included. Fourteen studies had a NOS score ≥ 7 points. NAFLD was diagnosed in 2162/6332 (34.1%) IBD participants. However, NAFLD diagnosis was established in 924/2962 (31.2%) healthy individuals without IBD. Advanced liver fibrosis was found in 116 (11.6%) of 992 IBD patients with NAFLD. Most studies found an association between NAFLD and classic cardiovascular risk factors such as older age, male sex, higher BMI, diabetes, hypertension and dyslipidemia. In addition, metabolic syndrome features were also associated with an increased risk of significant and advanced liver fibrosis. Although no strong association between NAFLD and IBD therapy was reported, some studies associated NAFLD with IBD diagnosis, Crohn’s Disease, a complicated course of IBD, disease activity, and IBD duration. Advanced liver fibrosis was also associated with Crohn’s disease in several studies. In conclusion, NAFLD and advanced liver fibrosis are prevalent and clinically relevant extraintestinal manifestations, so its diagnosis and potential progression to HCC should be carefully considered in daily clinical practice.
000126975 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000126975 590__ $$a4.5$$b2023
000126975 592__ $$a1.391$$b2023
000126975 591__ $$aONCOLOGY$$b78 / 322 = 0.242$$c2023$$dQ1$$eT1
000126975 593__ $$aOncology$$c2023$$dQ1
000126975 593__ $$aCancer Research$$c2023$$dQ2
000126975 594__ $$a8.0$$b2023
000126975 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion
000126975 700__ $$aGarcía-Mateo, Sandra$$uUniversidad de Zaragoza
000126975 700__ $$aLaredo, Viviana
000126975 700__ $$0(orcid)0000-0002-3545-2707$$aGargallo-Puyuelo, Carla J.$$uUniversidad de Zaragoza
000126975 700__ $$aGallego Llera, Beatriz
000126975 700__ $$0(orcid)0000-0002-2945-7368$$aLópez de la Cruz, Julia
000126975 700__ $$0(orcid)0000-0003-0076-3529$$aGomollón, Fernando$$uUniversidad de Zaragoza
000126975 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000126975 773__ $$g15, 13 (2023), 3367 [13 pp.]$$pCancers$$tCancers$$x2072-6694
000126975 8564_ $$s515748$$uhttps://zaguan.unizar.es/record/126975/files/texto_completo.pdf$$yVersión publicada
000126975 8564_ $$s2638755$$uhttps://zaguan.unizar.es/record/126975/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000126975 909CO $$ooai:zaguan.unizar.es:126975$$particulos$$pdriver
000126975 951__ $$a2024-11-22-12:03:25
000126975 980__ $$aARTICLE